Steven Mah
Stock Analyst at TD Cowen
(2.17)
# 2,880
Out of 4,981 analysts
29
Total ratings
37.04%
Success rate
10.49%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $25.31 | +129.16% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $25.51 | +21.52% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $10.01 | +1,098.80% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.83 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $18.57 | +126.17% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $4.47 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.64 | +509.76% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.55 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.43 | +764.20% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $168.51 | -8.02% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $21.86 | +540.44% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.17 | +4,344.44% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $95.12 | +336.29% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $28.57 | +775.04% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $25.31
Upside: +129.16%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $25.51
Upside: +21.52%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $10.01
Upside: +1,098.80%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.83
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $18.57
Upside: +126.17%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.47
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.64
Upside: +509.76%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.55
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.43
Upside: +764.20%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $168.51
Upside: -8.02%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $21.86
Upside: +540.44%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.17
Upside: +4,344.44%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $95.12
Upside: +336.29%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $28.57
Upside: +775.04%